Neuraworx develops bioelectronic solutions focused on enhancing the brain's natural waste clearance mechanisms. The company's core technology, Intelligent Cerebrovascular Pacing™, targets glymphatic system function to improve cerebral fluid homeostasis. This approach aims to facilitate the clearance of harmful biomolecules associated with declining brain health.
Funding
$610K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The brain's glymphatic system, responsible for clearing waste, declines with age, potentially contributing to the development of neurodegenerative diseases like Alzheimer's. Current treatments do not directly address the impaired waste clearance capacity in the brain.
Solution
NeuraWorxs is developing a bioelectronic device designed to enhance the brain's glymphatic system and improve cerebrospinal fluid (CSF) flow. The technology aims to stimulate the glymphatic system, facilitating the removal of metabolic waste products that accumulate in the brain. By improving CSF flow and waste clearance, NeuraWorxs seeks to address a key factor in the progression of neurodegenerative diseases. The device is intended to be a non-invasive or minimally invasive solution for enhancing the brain's natural waste removal processes.
Target Audience
The primary target audience includes individuals at risk of or affected by neurodegenerative diseases, such as Alzheimer's, and healthcare providers specializing in neurology and geriatric care.
Features
- Bioelectronic stimulation of the glymphatic system
- Enhancement of cerebrospinal fluid (CSF) flow
- Targeted waste clearance in the brain
- Non-invasive or minimally invasive device design